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Abstract
Cancer is one of the major life burdens and around 18.1 million new cancer 
cases and 9.6 million deaths have been estimated in 2018 globally. Recent reports 
of the World Health Organization (WHO) stated that about one in six death cases 
globally is mainly due to cancer. Hence, the development of efficacious drugs 
with novel mechanisms is necessary for various cancer types. The chemotherapy 
drug resistance and non-selectivity toward targets have turned the current cancer 
research on to the highly emerging selective targets for the development of potential 
anticancer agents. Benzimidazole is regarded as an essential pharmacophore of the 
cancer research because of wide anticancer potentials with versatile mechanisms to 
inhibit the tumor progression and also facile synthetic strategies for an easy syn-
thesis of various benzimidazole derivatives. The selective anticancer potentials also 
depend on the substitution of the benzimidazole nucleus. Therefore, it would lead 
to providing a path for the development of novel target-specific and highly effective 
benzimidazole-based anticancer agents.
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1. Introduction to cancer
Cancer is one of the dreadful diseases in the world and mainly characterized by 
uncontrolled cell proliferation. Worldwide, one in six women and one in five men 
develop cancer during their lifetime, and one in eleven women and one in eight men 
die from the disease. Global data clearly show that nearly half of the new cases and 
more than half of the cancer deaths worldwide in 2018 are estimated to occur in 
Asian countries because the region has nearly 60% of the global population and it 
is estimated to have a rise of over 21.4 million new cases per year, with 13.2 million 
cancer deaths, by 2030. The top three cancer types viz. breast, lung, and colorectal 
are responsible for one-third of the cancer incidence and mortality burden world-
wide [1, 2]. Behavioral risk factors such as tobacco usage and smoking; physical 
risk factors such as exposure to ionizing radiations and asbestos; and genetic 
predominant factors are the main contributors to cancer. Even though utmost care 
has been taken, the disease still causes the death of millions of people globally [3]. 
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Although scientific advances have focused on knowing the exact pathophysiology 
of the disease and tremendous efforts have been made on early diagnosis of cancer, 
the overall mortality rate has not subsided. Moreover, the cancer survival rate tends 
to be extremely low in some developing countries. This is due to the combination of 
both late-stage detection and limited access to time and qualitative treatment [4].
Radiotherapy, surgery, and chemotherapy are the usual cancer treatment strategies 
[5]. Among these, chemotherapy is considered as one of the efficient and first-line 
strategies in suppressing tumor prognosis and eradication. Most of the chemothera-
peutic drugs target the key cellular mechanisms and inhibit the cell division and 
thereby prevent cancer cell multiplication. Current clinical anticancer drugs usually 
act on metabolically effective or fast replicating cells and show drawbacks such as poor 
selectivity between cancer cells and healthy cells [6]. Cancer cells generally disturb the 
cell signaling pathways and tissue morphogenesis for the neoplastic propagation of 
tumors. Therefore, targeting these cell pathways by cytotoxic agents has been a proven 
therapeutic approach to subside tumor growth and disease progression. Unfortunately, 
most of the cytotoxic drugs cause side effects due to the poor selectivity and specific-
ity toward cancer cells. However, the higher toxic profiles and poor tolerance of the 
present chemotherapeutic drugs are major obstacles to the effective treatment of 
cancer [7, 8]. Therefore, it is highly pertinent to design and synthesize new anticancer 
agents with improved efficiency and reduced side effects to complement the present 
DNA interacting agents
Alkylating agents Alkylation of DNA bases
Procarbazine, dacarbazine, and temozolomide
DNA cleaving agents Cause strand scission at the binding site-Bleomycin
Cross-linking agents Binding to DNA results in intra- and inter-strand cross-linking
Platinum complexes-carboplatin, cisplatin, oxaliplatin
Nitrogen mustards-cyclophosphamide, ifosfamide
Intercalating agents Stacking between DNA base pairs
Anthracyclines-doxorubicin, epirubicin
Mitoxantrone and actinomycin-D
Topoisomerase inhibitors Topoisomerase I-camptothecins
Topoisomerase II-Anthracyclines, etoposide
Anti-metabolites
Purine analogues Mercaptopurine
Pyrimidine analogues 5-Fluorouracil
DHFR inhibitors Methotrexate
Antitubulin agents
Taxol Paclitaxel, Docetaxel
Vinca alkaloids Vincristine, Vinblastine, Vinorelbine
Tyrosine kinase inhibitors
Small molecule Imatinib (Gleevec): inhibits ABL, c-Kit kinase, PDGFR
Gefitinib (Iressa): inhibits EGFR
Monoclonal antibody Trastuzumab: inhibits EGFR2, HER2
Angiogenesis/ Metastasis inhibitors
Monoclonal antibody Bevacizumab (Avastin): targets VEGF
Table 1. 
Common anticancer drugs along with their mechanisms of action.
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chemotherapeutic approaches. Identifying new drugs and drug  combinations for 
cancer treatment is essential to combat this lethal disease. Hence, further research 
that emphasizes mainly on the development of efficient chemotherapeutic agents is 
an emerging area of research in the field of medicinal chemistry. The list of various 
available chemotherapeutic agents has been shown in Table 1 [9].
2. Introduction to Benzimidazole
Benzimidazole heterocyclic nucleus can be termed as “Master Key” due to its 
overwhelming biological profile and synthetic applications in medicinal chem-
istry. It is among the top five most common five-membered aromatic nitrogen 
heterocycles in U.S. FDA-approved pharmaceutical drugs [10]. Benzimidazoles 
are structural isosteres of nucleobases due to the fused nitrogen nuclei and they 
readily interact with biomolecular targets and elicit many biological activities such 
as anticancer [11], anti-inflammatory [12], antiulcer [13], anti-hypertensive [14], 
and anthelmintic [15]. Akhtar et al. in his recent review described the therapeutic 
evolution of benzimidazole scaffolds during the last quinquennial period [16]. 
This nitrogen-containing heterocycle was present in a number of well-established 
clinical drugs with diverse therapeutic activities. For instance, drugs like rabepra-
zole (1) and omeprazole (2) are benzimidazole-containing drugs, act as proton 
pump inhibitors, and are, therefore, used in the treatment of stomach ulcers [17]. 
Albendazole (3) and thiabendazole (4) are anthelmintic drugs that act by the 
inhibition of tubulin polymerization and impair the uptake of glucose, eventually 
leading to the death of the parasites [18]. Nocodazole (5) is a well-recognized anti-
neoplastic agent that mainly acts by tubulin polymerization inhibition. Candesartan 
(6) is a benzimidazole-based orally active potent angiotensin II receptor antagonist 
that is used for the treatment of hypertension [19]. Bendamustine (7) is nitrogen 
mustard which belongs to alkylating agents, a class of chemotherapeutic agent 
and used in the treatment of chronic lymphomas [20]. Dovotininb (8) is the orally 
active benzimidazole quinolinone compound with potential antineoplastic activ-
ity (Figure 1). It strongly binds to the fibroblast growth receptor 3 (FGFR3) and 
inhibits its phosphorylation and induces tumor cell death [21].
Figure 1. 
Examples of drugs and other bioactive molecules containing benzimidazole motif.
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In 1954, Tamm, Folkers, and co-workers first reported the synthesis and anti-
viral activities of halogenated benzimidazole nucleosides [22]. They found that 
5,6-dichloro-1-β-D-ribofuranosyl benzimidazole (DRB) has multiple biological 
activities including activity against RNA and DNA viruses. DRB inhibits cellular 
RNA polymerase II, thus affecting the multiple cellular processes so that it is more 
cytotoxic than antiviral. Slayden et al. found that albendazole (3) and thiaben-
dazole (4) known tubulin inhibitors interfered and delayed the Mtb cell division 
processes [23]. Later, Kumar et al. proposed that the benzimidazole core would be a 
novel FtsZ inhibitor, which will have activity against both drug-sensitive and drug-
resistant Mtb [24]. This molecular framework displays numerous biological proper-
ties and is usually present in various drug compositions. Benzimidazoles tethered to 
various bioactive pharmacophores have also displayed potent antitumor activities.
Benzimidazoles have revolutionized the drug discovery process by their diverse 
range of biological activities, which make this scaffold an indispensable anchor for 
the innovation of novel therapeutic agents. Thus, the therapeutic potential of the 
benzimidazole and related drugs has attracted researchers to design and synthesize 
more potent derivatives with a wide range of pharmacological activities. Owing to 
the immense synthetic value and extended bioactivities exhibited by benzimid-
azoles and their derivatives, efforts have been made from time to time to create 
libraries of these compounds.
3. Target-based benzimidazole derivatives
3.1 Galectin-1 inhibitors
Galectin-1 (Gal-1) is expressed in various normal and pathological conditions 
and has multiple functions with a wide range of biological activity. Gal-1, a human 
homodimeric lectin protein of 14KDa, is implicated in many signaling pathways, 
immune responses associated with cancer progression, neurological conditions, and 
immune disorders [25]. Gal-1 has a carbohydrate recognition domain (CRD), which 
is selective toward β-galactosides in the body. Inhibition of human Gal-1 has been 
regarded as one of the potential therapeutic approaches for the treatment of cancer, 
as it plays a major role in tumor development and metastasis by modulating vari-
ous biological functions viz. angiogenesis, apoptosis, migration, and cell immune 
escape [26]. The overexpression of Gal-1 has been reported in many cancer types 
like the brain, breast, osteosarcoma, lung, prostate, melanoma, etc. [27]. Gal-1 can 
mediate neoplastic transformation by interacting with oncogenes, such as H-Ras 
and promote Ras-mediated signal transduction involving RAF1 and extracellular 
signal-regulated kinase (ERK). Gal-1 multivalently mediates tumor cell-ECM adhe-
sion at the primary site by cross-linking cell surface glycoproteins, such as integrins, 
and glycosylated proteins in the ECM, such as laminin and fibronectin [28]. Hence, 
Gal-1 is regarded as a promising molecular target for the development of new 
therapeutic drugs for cancer.
Recently, a new series of 1-benzyl-1H-benzimidazole derivatives have been 
synthesized as Gal-1-mediated anticancer agents. The target compound (9) showed 
significant growth inhibition against breast cancer (MCF-7) cells with an IC50 
value of 7.01 ± 0.20 μM. The target compound also showed good cytotoxicity in 
the range of 10.69–14.04 μM against colorectal cancer (HCT-116), breast cancer 
(MDA-MB-231), prostate cancer (DU-145), and lung cancer (A-549). In addition, 
in-vitro Gal-1 expression in cell supernatant of MCF-7 cells with compound (9) was 
measured in enzymatic GAL-1 ELISA studies and found to show dose-dependent 
reduction from 10 to 300 μM. The target compound showed Gal-1-mediated 
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apoptosis, which was confirmed by morphological changes in MCF-7-treated cells 
like blebbing, cell wall deformation, and cell shrinkage, based on the apoptosis 
studies such as Acridine Orange/Ethidium Bromide (AO/EB) staining, DAPI nucleic 
acid staining, mitochondrial membrane potential, annexin V/propidium iodide dual 
staining assay, and dichlorofluorescein (DCF) fluorescence studies. In cell cycle 
analysis, the target compound selectively arrested MCF-7 cell growth at the G2/M 
phase and S phase. Further, the binding specificity of target compound toward 
Gal-1 was confirmed by surface plasmon resonance and fluorescence spectroscopy 
studies and the specific binding constant value (Ka) of 1.2 × 10
4 M−1 was observed 
in fluorescence spectroscopy studies, whereas the equilibrium constant (KD) value 
of 5.76 × 10−4 M was observed in surface plasmon resonance studies. The bind-
ing of the target compound to Gal-1 was also confirmed by RP-HPLC studies and 
found to show 85.44% of binding to Gal-1. The molecular docking studies were also 
supported based on the strong amino acid interactions such as ARG48, TRP68, and 
ASP125 with the target compound [29, 30].
Tsung-Chieh Shih et al. reported a novel Gal-1 inhibitor named LLS2 (10), 
which was discovered through the One-Bead-Two-Compound library. The inter-
action of target gal-1 with LLS2 was confirmed by LC-MS/MS analytical and 
pull-down assay. The binding complex of LLS2 with Gal-1 selectively decreases 
membrane-specific H-Ras, and K-Ras pathways, lead to involve in the apoptosis 
process. The LLS2 exhibited a synergistic effect in combination with paclitaxel 
against many of the human cancer cell lines such as pancreatic cancer, ovarian 
cancer, and breast cancer cells in vitro. The combination of paclitaxel with LLS2 
efficiently reduces the growth of ovarian cancer xenografts in athymic mice in vivo 
(Figure 2).
The same group recently published a more potent Gal-1 inhibitor LLS3 (11), it 
impairs castration-resistant prostate cancer progression and invasion. LLS3 targets 
Gal-1 as an allosteric inhibitor, and reduces Gal-1 binding affinity toward its bind-
ing partners and also causes suppression of Akt, and AR signaling pathways. LLS3 
showed in vivo efficacy in both androgen receptor-positive and negative xenograft 
models. In addition to potentiating the anticancer effect of docetaxel to cause sup-
pression of tumors, it also efficiently suppresses the progression of prostate cancer 
cells in vivo [31, 32].
3.2 Tubulin protein inhibitors
Tubulin is one of the members of a small family of globular proteins. Several 
isoforms are present out of which α- and β-tubulins are the most common members 
of tubulin. The cellular protein tubulin is an important protein for replication. 
Figure 2. 
The novel benzimidazole derivatives as Gal-1 mediated anticancer agents.
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Microtubules are hallowing filaments and composed of head and tail polar fashion 
arrangements of α- and β-tubulins as the constituent subunits. Microtubules con-
tain 13 active protofilaments aligned parallel with the whole axis of the microtubule 
cylinder. This may provide continuous transport of cellular materials by motor pro-
teins (dynein and kinesin) over distant places. Microtubules also form an integral 
part of the cytoskeleton and are responsible for the maintenance of cell shape, and 
motility and intracellular transport of the vesicles, mitochondria, and other com-
ponents [33, 34]. Moreover, cell division involves the duplication of DNA and the 
segregation of the replicated chromosomes into two daughter nuclei. The segrega-
tion of these chromosomes is mitotic phase is brought by the microtubules. In the 
formation of the microtubule, the plus (+) end is terminated by β-tubulin whereas 
the minus (−) end is terminated by α-tubulin. They are always either in a state of 
polymerization or depolymerization. Microtubules have the ability to shorten or 
lengthen in a scholastic fashion through loss or addition of α/β-tubulin heterodi-
mers from ends of microtubules. This property is referred to as “dynamic instabil-
ity” [35, 36]. Microtubules are blessed with a property to grow continuously as long 
as the free tubulin amount is above a critical level. The critical concentration at the 
minus end is somewhat higher than at the plus end and the minus end tends to stop 
growing first. Even above the critical tubulin concentration, its end may suddenly 
stop growing and begin to shrink. The change from growth to shrinkage has been 
termed as “catastrophe.” After some time, a shrinking microtubule end may “pause” 
and/or begin to grow again; the latter process is known as “rescue.” During mitotic 
cell division, the chromosomes are segregated by the mitotic spindle, which is 
formed from tubulin microtubules. Therefore, tubulin dynamics have a distinct role 
in cell division. Some of the drugs affect the microtubulin dynamics and thus cause 
either polymerization or depolymerization and thereby alter cellular replication. 
So at the mechanistic level, tubulin is one of the most attractive and challenging 
approaches for designing new anticancer compounds.
Zhang et al. have synthesized a series of 1,2-diarylbenzimidazole derivatives 
and reported as potential anticancer agents. Among all, the target molecule (12) 
has been found to show significant cytotoxicity against human cancer cells such 
as A549, HepG2, HeLa, and MCF-7 cells in the range of GI50 = 0.71–2.41 μM and 
also found to show normal cytotoxicity toward normal cells. The apoptosis process 
by the target compound was confirmed by morphological changes on HepG2 and 
HeLa-treated cells like cell wall deformation, blebbing, and cell shrinkage, based on 
apoptosis studies such as mitochondrial membrane potential, annexin V/propidium 
iodide dual staining assay, and dichlorofluorescein (DCF) fluorescence studies. 
In cell cycle analysis, the target compound selectively arrested tumor growth at 
the G2/M phase. Further, the target compound showed significant inhibition of 
microtubule polymerization with an IC50 value of 8.47 μM. The molecular docking 
simulation studies were performed to confirm the binding of the target compound 
with microtubule protein and found that the target compound has made strong 
interactions with protein [37].
Miao et al. reported a novel series of 2-aryl-benzimidazole-based dehydroabietic 
acid derivatives as potential cytotoxic agents via targeting tubulin polymeriza-
tion. The synthesized molecules were characterized by elemental and analytical 
techniques. The target compound (13) showed significant growth inhibition 
against hepatocarcinoma cancer (SMMC-7721) cells with an IC50 value of 
0.08 ± 0.01 μM. The target compound also showed good cytotoxicity in the range 
of 0.04–0.07 μM against breast cancer (MDA-MB-231), cervical cancer (HeLa), 
and colon cancer (CT-26). The apoptosis studies such as ROS levels measurements, 
loss of mitochondrial membrane potential, and cell cycle analysis were performed 
to confirm the induction of apoptosis in hepatocarcinoma cancer (SMMC-7721) 
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cells. In cell cycle analysis, the target compound selectively arrested tumor growth 
at the G2/M phase. Further, the target compound showed significant inhibition of 
microtubule polymerization with an IC50 of 5 μM. The molecular docking studies 
supported the selectivity of the target compound to tubulin protein based on strong 
electronic interactions between the target compounds and tubulin [38].
Wang et al. reported a new series of benzimidazole containing benzsulfamide-
pyrazole ring derivatives as potential tubulin polymerization inhibitors. The 
target compound (14) showed significant growth inhibition against lung cancer 
(A549) cells with an IC50 value of 0.15 ± 0.05 μM and also showed good growth 
inhibition against Hela, HepG2, and MCF-7 cell lines in the range of 0.17–0.33 μM 
concentration. Further, the target compound showed significant inhibition of 
microtubule polymerization with an IC50 value of 1.52 μM. In cell cycle analysis, 
the target compound selectively arrested A549 cell growth at the G2/M phase. The 
target compound showed A549 cell apoptosis based on the studies of annexin V/
propidium iodide dual staining assay and cell cycle analysis. The molecular docking 
studies were also supported based on the strong amino acid interactions such as LYS 
352, LYS 254, ASN 258, and CYS 241 with the target compound [39] (Figure 3).
Baig et al. have reported a series of imidazo [2,1-b] thiazole-benzimidazole 
derivatives as antiproliferative agents via tubulin polymerization inhibition. The 
target molecule (15) has shown significant cytotoxicity against human lung (A549) 
cancer with an IC50 value of 1.08 μM. It also showed good cytotoxicity toward 
DU-145 (prostate), MCF-7 (breast cancer), A549 (lung cancer), and HeLa (cervi-
cal cancer) in the range of 1.65–7.55 μM. In cell cycle analysis, the target compound 
selectively arrested A549 cell growth at the G2/M phase. The target compound 
showed apoptosis, which was confirmed by morphological changes in A549-treated 
cells like blebbing, cell wall deformation, and cell shrinkage, based on the apoptosis 
studies such as Hoechst staining, mitochondrial membrane potential, annexin V/
propidium iodide dual staining assay. Further, the target compound exhibits a 
significant inhibition of microtubule assembly with an IC50 of 1.68 μM. The com-
putational studies revealed that the target compound can easily be occupied in the 
colchicine binding site of the protein [40].
3.3 Carbonic anhydrase inhibitors
The human carbonic anhydrases (hCAs) are an α-family of carbonic anhydrases 
class and exist in 16 different isoforms [41]. Based on their location in the body, 
Figure 3. 
The target benzimidazole derivatives as selective anticancer agents via targeting tubulin polymerization.
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they are classified into cytosolic hCAs such as CA I, CA II, CA III, CA VII, and CA 
XIII; transmembrane hCAs such as CA IV, CA IX, CA XII, CA XIV, and CA XV; 
mitochondrial-bound hCAs such as CA Va and Vb; secretory hCAs such as CA VI; 
and catalytically inactive isoforms like CA VIII, CA X, and CA XI, which are consid-
ered as CA-related proteins (CARPs) [42]. Among all, the hCA isoforms IX and XII 
are overexpressed in many of cancer types as these are tumor-associated transmem-
brane bound enzymes, mainly hypoxic tumors, which are regarded as emerging 
potential targets for various tumor types [43]. The overexpression of hCA isoforms 
IX and XII further contributes to the tumor progression, angiogenesis, metastasis, 
and proliferation of a variety of tumor cells [44]. In order to exhibit potential 
cytotoxicity without adverse effects, an anticancer agent should selectively inhibit 
tumor-associated hCAs IX and XII over other hCAs. Therefore, current cancer 
research focuses on the development of various heterocycles that selectively target 
tumor-linked hCA isoforms IX and XII for effective treatment strategies in cancer 
therapy [45]. Another hCA isoform II is also found to overexpress in some forms of 
cancer and other conditions like edema, glaucoma, and epilepsy.
Recently, a new series of 2-substituted-benzimidazole-6-sulfonamides have been 
reported as anticancer potentials by testing against four physiologically relevant 
hCAs such as CA I, CA II, CA IX, and CA XII. The analysis of hCA inhibition results 
showed that the new series of benzimidazole-based sulfonamide derivatives exhib-
ited selective inhibition toward tumor-associated isoforms such as CA IX and CA 
XII. The target molecule (16) of this series had shown a promising inhibition at low 
μM range against hCA IX and XII isoform, with an inhibitory constant (Ki) value of 
2.2 and 22.3 μM. Another potent compound (17) also exhibited good inhibition at 
low μM range against hCA IX and XII, with an inhibitory constant (Ki) value of 5.9 
and 7.9 μM respectively. Hence, it is concluded that these benzimidazole derivatives 
might be potential anticancer agents exhibiting a novel mechanism through inhibi-
tion of hCA isoforms IX and XII [46]. Asta Zubriene et al. have reported a series 
of novel benzenesulfonamides with benzimidazole derivatives as selective human 
carbonic anhydrase I, II, VII, XII, and XIII inhibitors. The target molecules were 
synthesized from the precursor benzimidazole derivative with different phenacyl 
bromides. The target molecules (18, 19) were evaluated against five physiologi-
cal relevant hCA isoforms (hCA, EC 4.2.1.1) CA I, CA II, CA VII, CA XII, and 
CA XIII. The target compound exhibited a promising inhibitory action at a lower 
nanomolar level against selected hCAs with an inhibitory constant (Ki) value range 
of 1.67–66.7 μM. Another target molecule has shown significant inhibition at lower 
nanomolar level against selected hCAs with an inhibitory constant (Ki) value range 
of 2.86–62.5 μM [47] (Figure 4).
3.4 Epidermal growth factor receptor (EGFR) inhibitors
The Epidermal Growth Factor Receptor is a subfamily transmembrane glyco-
protein (ErbB-1) of ErbB class of tyrosine kinase receptors and, other subfamilies 
include HER2/neu (ErbB-2), Her 3 (ErbB-3) and, Her 4 (ErbB-4) [48]. The inter-
nal ligands like EGF and TGF𝛼 facilitate the growth-promoting signal to cells by 
interacting with EGFR receptors and regulate epithelial tissue development and 
homeostasis [49, 50]. In cancer, especially epithelial malignancies, due to overpro-
duction of EGFR ligands in the tumor micro environment causes continual activa-
tion (or) mutations of EGFR receptors, result in enhances epithelial tumor growth, 
metastasis and invasion [51, 52].
In a recent study, a new series of benzimidazole-based triazole and thiadiazole 
derivatives were synthesized and evaluated as selective EGFR inhibitors. The single-
crystal X-ray crystallographic analysis has been performed to confirm the molecular 
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structure of the target compound. The synthesized compounds were evaluated for 
their EGFR kinase inhibitory potencies with erlotinib as the reference standard and, 
most of the compounds showed promising activities. The cell inhibition studies 
were also performed and the target compound (20) exhibited a significant inhibi-
tion and exhibited EGFR kinase inhibitory activity (over ≥30%) against MCF7 
cells. The molecular docking studies indicated that the target compound showed 
two-hydrogen bonding interactions with residues of LYS721 and THR830 at the 
binding site of EGFR tyrosine kinase [53]. Akhtar et al. reported the benzimid-
azole-oxadiazole hybrids as selective EGFR and erbB2 receptor inhibitors. In in vitro 
cell inhibition studies, the target compound (21) exhibited a significant inhibition 
with an IC50 of 5.0 μM against breast cancer (MCF-7) cells. The target compound 
was found to show significant inhibition of EGFR and erbB2 receptor at 0.081 
and 0.098 μM respectively. Most of the synthesized compounds exhibited a good 
cytotoxic activity against selected human cancer cell lines. In cell cycle analysis, the 
target compound selectively arrested MCF-7 cell growth at the G2/M phase. The 
computational and 3D-QSAR studies indicated that the target compound exhibited 
strong interactions with Asp831, Met769, and Thr830 of the EGFR enzyme [54].
Akhtar et al. have synthesized benzimidazole-based pyrazole derivatives 
through a one-pot multicomponent reaction and evaluated them for their poten-
tial anticancer activities. The synthesized compounds were screened against 
selected human cancer cell lines such as MCF-7, MDA-MB231, A549, HepG2, and 
HaCaT. The evaluation of EGFR inhibitory activities was performed for all the syn-
thesized compounds. The target compound (22) exhibited promising cytotoxicity 
against the lung (A549) cancer cell lines with an IC50 value of 2.2 mM and the EGFR 
receptor inhibition value with an IC50 of 0.97 mM. In cell cycle analysis, the target 
compound selectively arrested A549 cell growth at the G2/M phase. In addition, 
it suppressed the growth of lung cancer cells by inducing apoptosis. In molecular 
docking studies, the target compound showed strong electronic interactions with 
Met769, Thr830, Lys721, and Phe699 of the active pocket of the EGFR receptor [55]. 
Yuan et al. have synthesized a library of 6-amide-2-aryl benzoxazole/benzimid-
azole derivatives and evaluated them for their selective inhibitory activities against 
VEGFR-2. The library of compounds exhibited selective anticancer activity against 
the liver hepatocellular carcinoma (HepG2), and human umbilical vein endothelial 
cells (HUVECs) over the lung cancer (A549) and breast (MDA-MB-231) cancer 
Figure 4. 
The benzimidazole derivatives as human carbonic anhydrase enzyme mediated anticancer agents.
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cell lines. The target compound exhibited a significant growth inhibition against 
HepG2 and HUVEC with IC50 values of 1.47 and 2.57 mM, respectively. The target 
compound (23) showed anti-angiogenesis ability (79% inhibition at 10 nM/eggs) 
by chick chorioallantoic membrane (CAM) assay and exhibited excellent VEGFR-2 
kinase inhibition with an IC50 of 0.051 mM. The computational analysis showed 
that the target compound made strong interactions with the active site of VEGFR-2 
kinase. It is concluded that the 6-amide-2-arylbenzoxazole/benzimidazole deriva-
tives are essential inhibitors of VEGFR-2 kinase for the treatment of anti-angiogen-
esis [56] (Figure 5).
4. Miscellaneous agents
Wu et al. synthesized a series of novel benzimidazole-2-substituted phenyl or 
pyridine propyl ketene derivatives and two representative compounds (24) and 
(25) showed significant inhibitory activity against colorectal (HCT116), breast 
(MCF-7), and liver (HepG2) cell lines, and effective inhibition of tumor growth in 
BALB/c mice with colon carcinoma HCT116 cells [57]. Reddy et al. reported a series 
of pyrazole-containing benzimidazole hybrids and evaluated them for their poten-
tial anti-proliferative activity against lung (A549), breast (MCF-7), and cervical 
(HeLa) cell lines. The compounds (26) and (27) showed potent growth inhibition 
against all the cell lines tested, with IC50 values in the range of 0.83–1.81 μM [58]. 
Gowda et al. synthesized a series of novel 1-(4-methoxyphenethyl)-1H-benzimid-
azole-5-carboxylic acid derivatives and the compound (28) induced maximum cell 
death in leukemic cells (K562 and CEM cell lines), through inducing apoptosis via 
S/G2 cell cycle arrest; down regulation of CDK2, Cyclin B1 and PCNA; cleavage of 
PARP; and elevated levels of DNA strand breaks [59]. Akhtar et al. reported a series 
of benzimidazole-linked oxadizole hybrids and the compounds were screened for 
their anticancer and in vitro EGFR and erbB2 receptor inhibition assay. Two of the 
compounds (29) and (30) displayed promising activity. The compound 70a showed 
EGFR inhibition and induced apoptosis by G2/M cell cycle arrest [54] (Figure 6).
5. Synthetic strategies
The first benzimidazole (2,5-dimethylbenzimidazole) (3) or 2,6-dimethyl-
benzimidazole (4) was prepared in 1872 by Hoebrecker through reduction of 
Figure 5. 
The benzimidazole derivatives as selective anticancer agents via targeting EGFR.
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2-nitro-4-methylacetanilide [60] (1) (Figure 7). Several years later, the synthesis of 
benzimidazole was reported by refluxing 3,4-diamino toluene (2) with acetic acid 
[61]. Many synthetic ways toward the construction of benzimidazole ring started 
Figure 6. 
The novel benzimidazole derivatives as potential anticancer agents.
Figure 7. 
General syntheses of benzimidazoles from aniline derivatives.
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from commercially available benzene derivatives containing nitrogen functional-
ities, especially ortho derivatives. Hence, a number of methods have been reported 
for the synthesis of bioactive benzimidazoles and their derivatives. The majority of 
these involve the condensation of O-phenylene diamines (5) and its derivatives with 
carboxylic acids (6), esters, alcohols, or aldehydes [62].
Synthesis of benzimidazoles in the presence of various catalysts involves the 
condensation of O-phenylene diamines with ortho esters in the presence of Lewis 
acids like ZrCl4, SnCl4, TiCl4, HFCl4, etc. The most commonly used method for syn-
thesis of benzimidazoles (7) is Phillip’s method, which involves the condensation of 
O-phenylene diamines (5) with carboxylic acids (6) or its derivatives by heating the 
reagents in the presence of concentrated hydrochloric acid [62] (Figure 8).
The benzimidazole derivatives (14) were synthesized under mild conditions 
with inherently low cost by many researchers using (8), (9), (10), (11), (12), 
and (13), as reactants (Figure 9). Suheyla et al. demonstrated the synthesis of 
benzimidazoles by condensation of O-phenylene diamine with an appropriate 
aldehyde (8) in the presence of sodium metabisulfite. They proposed the reac-
tion that depends on forming the bisulfite adduct of the aryl aldehyde to prepare 
benzimidazole.
Hanan et al. have reported one-pot conversion of aromatic and heteroaromatic 
2-nitroamines (9) into bicyclic 2H-benzimidazoles employs formic acid, iron 
Figure 9. 
Synthetic strategies of benzimidazoles.
Figure 8. 
Phillip’s condensation for the synthesis of benzimidazoles.
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powder, and NH4Cl as an additive to reduce the nitro group and effect the imidazole 
cyclization with high-yields [63]. Nale et al. developed a method for the synthesis 
of benzimidazole derivatives in the presence of zinc catalysts from N-substituted 
formamides and various o-phenylenediamines [64] (10). Mahesh et al. developed a 
method of one-pot, multicomponent reaction, which enables the transformation of 
commercial aryl amines, aldehydes, and azides (11) into various benzimidazoles via 
an efficient copper-catalyzed amination of N-aryl imines [64]. Lin et al. developed 
a method for solvent/oxidant-switchable synthesis of multisubstituted benzimid-
azoles via metal-free selective oxidative annulation of arylamidines [65] (12). Wray 
et al. synthesized various N-aryl-1H-indazoles and benzimidazoles from common 
arylamino oximes (13) in good to excellent yields [66].
6. Conclusion
There are numerous benzimidazole derivatives for various cancer types involv-
ing unique types of mechanism. Although it is a widely used pharmacophore, still 
very few target-specific benzimidazoles are available. Therefore, researchers across 
the world need to develop new benzimidazole derivatives that are more target 
specific and help in the cancer treatment to overcome non-selective toxicity and 
adverse effects. This chapter mainly focused on target-based benzimidazole deriva-
tives and synthetic strategies. Hence, it would give more ideas to young medicinal 
researchers to develop target-specific benzimidazole derivatives as potential 
cytotoxic agents.
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